Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 4, 2025

Recombinant Anti-Granzyme B antibody [EPR22645-206]

RRID:AB_2860567
Type: Antibody

Proper Citation

(Abcam Cat# ab255598, RRID:AB_2860567)

Antibody Information

URL: http://antibodyregistry.org/AB_2860567

Proper Citation: (Abcam Cat# ab255598, RRID:AB_2860567)

Target Antigen: Granzyme B

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, IHC-Fr, IP

Antibody Name: Recombinant Anti-Granzyme B antibody [EPR22645-206]

Description: This recombinant targets Granzyme B

Target Organism: Human, Mouse

Clone ID: EPR22645-206

Antibody ID: AB_2860567

Vendor: Abcam

Catalog Number: ab255598

Record Creation Time: 20231110T032037+0000

Record Last Update: 20240725T064320+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

No alerts have been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell metabolism.

Franzolin G, et al. (2024) PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. Cancer immunology research, 12(9), 1286.

Wang X, et al. (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer cell, 42(10), 1729.

Liu X, et al. (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer cell, 41(2), 272.

Tang R, et al. (2023) Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell reports. Medicine, 4(10), 101234.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med (New York, N.Y.), 4(6), 373.

Tian T, et al. (2023) FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell reports, 42(11), 113362.

Mise Y, et al. (2022) Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis, 43(7), 647.

Wang L, et al. (2022) PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. Cell reports, 41(2), 111462.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(23), 5190.

Shiao SL, et al. (2021) Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer cell, 39(9), 1202.

Kaddatz H, et al. (2021) Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. Glia, 69(4), 925.